Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.42 USD | +1.16% | +1.07% | +15.71% |
04-23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
04-23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.71% | 1.43B | |
+2.90% | 108B | |
+10.29% | 104B | |
+1.83% | 22.33B | |
-11.88% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.08% | 17.64B | |
+6.04% | 14.05B | |
+36.23% | 12.51B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Wedbush Raises Kiniksa Pharmaceuticals Price Target to $21 From $20, Maintains Outperform Rating